sufentanil (Sufenta,Dsuvia)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Sufenta. DEA-controlled substance: class 2.

Indications

Contraindications

concurrent use of MAO inhibitors

pregnancy category = c

safety in lactation = ?

Dosage

Injection: 50 ug/mL (1 mL, 2 mL, 5 mL).

Pharmacokinetics

  • rapid onset of action (1-3 minutes)
  • duration of action 45-90 minutes
  • metabolized by the liver by cyt P450 3A4
  • eliminated mostly as inactive drug in the urine
  • triphasic elimination
  • terminal 1/2life of 2-2.5 hours

elimination via liver

1/2life = 2-2.5 hours

Adverse effects

Drug interactions

Mechanism of action

More general terms

Additional terms

Component of

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
  3. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  4. Prescriber's Letter 13(3): 2006 Cytochrome P450 drug interactions Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220233&pb=PRL (subscription needed) http://www.prescribersletter.com
  5. Brooks M FDA Goes Ahead With Approval of Sufentanil Despite Controversy. Medscape - Nov 02, 2018. https://www.medscape.com/viewarticle/904330
    FDA Statement. Nove 2, 2018 Statement from FDA Commissioner Scott Gottlieb, M.D., on agency's Dsuvia and the FDA's future consideration of new opioids. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm624968.htm
    FDA ADVISORY COMMITTEE BRIEFING DOCUMENT DSUVIA <TM> (sufentanil) sublingual tablet, 30 mcg AcelRx Briefing Document. FDA Advisory Committee Meeting Nov, 2018 https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM622858.pdf

Database